|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, September 12, 2018 ) The viral vector manufacturing market is expected to reach USD 815.8 million by 2023 from an estimated USD 327.8 million in 2018, at a CAGR of 20.0%.
The major players in the global market are Lonza (Switzerland), Merck (Germany), Oxford BioMedica (UK), CGT Catapult (UK), Cobra Biologics (UK), uniQure (Netherlands), FUJIFILM Diosynth Biotechnologies (US), and Spark Therapeutics (US).
Download Here for Free Sample Papers of Viral Vector Manufacturing Market with Top Trends and Company Profile at http://www.rnrmarketresearch.com/contacts/request-sample?rname=1607205 .
Pages-107 Tables-50 Figures-22 Profiles-14
There are several types of viral vectors that can be used to deliver nucleic acids into the genetic makeup of cells including retrovirus, lentivirus, adenovirus, and herpes simplex virus–each with its own advantages and disadvantages for specific applications.
Viral Vector Manufacturing Market, By Disease
1 Introduction
2 Cancer
3 Genetic Disorders
4 Infectious Diseases
5 Other Diseases
Viral Vector Manufacturing Market, By Application
1 Introduction
2 Gene Therapy
3 Vaccinology
The growth of this market is expected to be driven by rising prevalence of target diseases and disorders, the availability of funding for gene therapy development, effectiveness of viral vectors in gene therapy delivery, and ongoing research into viral vector-based gene & cell therapies.
Competitive Landscape
1 Overview
2 Product Approval
3 Collaborations, Partnerships, and Agreements
4 Acquisitions and Mergers
5 Expansions
North America is expected to account for the largest share of 64.8% of the global viral vector manufacturing market. Factors such as a large number of regenerative medicine companies (including gene and cell therapy companies), increasing research activities, rising prevalence of target diseases, and availability of funding are supporting the growth of the viral vector manufacturing market in North America.
Break of primary participants was as mentioned below:
• By Company Type – Tier 1–40%, Tier 2–30% and Tier 3–30%
• By Designation – C-level–20%, Director Level–40%, Others–40%
• By Region – North America–50%, Europe–20%, Asia Pacific–20%, RoW–10%
Click Now for More Details on “Viral Vector Manufacturing Market by Type (Retrovirus, Gammaretrovirus, AAV), Disease (Cancer, Infectious Disease, Genetic Disorders), Application (Gene Therapy, Vaccinology), End User (Biotech companies, Research Institutes) - Global Forecast to 2023” report at http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=1607205 .
The report will help established firms as well as new entrants/smaller firms gauge the pulse of the market, which in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their position in the market.
Target Audience
1 Pharmaceutical and biotechnology companies
2 Viral vector developers
3 Contract development and manufacturing organizations (CDMOs)
4 Business research and consulting firms
5 Research institutions
6 Venture capitalists
List of Tables
1 Approved Viral Vector Gene Therapies
2 Number of Clinical Trials Registered on Various Viral Vectors Globally
3 Viral Vector Manufacturing Market, By Type, 2016–2023 (USD Million)
4 Viral Vector Manufacturing Market for Retroviral Vectors, By Type, 2016–2023 (USD Million)
5 Viral Vector Manufacturing Market for Retroviral Vectors, By Region, 2016–2023 (USD Million)
Order this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=1607205 .
ReportsnReports
Mr. Hrishikesh
+ 18883915441
sales@rnrmarketresearch.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
